Telomir Pharmaceuticals, Inc. (TELO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc. on March 31, 2026. The Company is an emerging growth company incorporated in Florida, with its principal executive offices in Miami. The filing reports a significant corporate event under Item 8.01 regarding the advancement of its lead investigational candidate.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or operational financial data.
Material Changes and Corporate Events
- IND Submission: On March 31, 2026, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-1 (Telomir-Zn).
- Indication: The application targets the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).
- Drug Mechanism: Telomir-1 is a first-in-class, small-molecule metal-modulating epigenetic therapy. It functions by reducing redox-active iron and increasing zinc availability, thereby inhibiting iron-dependent epigenetic enzymes (histone demethylases).
- Preclinical Data: The submission includes data from completed pharmacology, toxicology, and manufacturing studies. Preclinical models showed reduced tumor growth and metastatic dissemination in TNBC, with no treatment-related adverse or dose-limiting toxicities observed in GLP safety studies.
Guidance, Outlook, and Management Commentary
- Clinical Trial Plan: Subject to FDA clearance, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-1 as an oral monotherapy.
- Study Design: The Phase 1 portion will use a standard 3+3 dose-escalation design to assess safety and determine a recommended Phase 2 dose. The Phase 2 portion will utilize a Simon two-stage design with objective response rate as the primary endpoint.
- Future Activities: The Company is continuing to evaluate Telomir-Zn in additional preclinical models and advancing biomarker strategies. It plans to present data at scientific conferences, including the AACR Annual Meeting 2026, and has submitted manuscripts to peer-reviewed journals.
- Risks: The initiation of clinical trials is contingent upon FDA clearance of the IND application.
Investor Verification Checklist
- Confirm the FDA's decision on the IND application for Telomir-1 (Telomir-Zn).
- Monitor the timeline for the initiation of the Phase 1/2 clinical trial in TNBC patients.
- Review upcoming presentations at the AACR Annual Meeting 2026 for updated preclinical data.
- Assess the Company's cash runway and capital requirements, as this filing does not disclose current liquidity levels.